Supplements
Download PDF

This activity is no longer available for credit, however its content is still (may still be) relevant for your educational needs.

Valid: May 13th, 2011 - May 13th, 2012

Statement of Need
The purpose of this activity is to enhance knowledge concerning the treatment of patients with MM.


Target Audience
The educational design of this activity addresses the needs of physicians, nurses, and pharmacists involved in the treatment of patients with multiple myeloma (MM).


Learning Objectives
After completing this activity, the participant should be better able to:

  • Describe the rationale for implementing maintenance therapy for patients with MM
  • Explain how specific patient- and disease-related factors impact the choice of maintenance therapy in MM
  • Review recent safety and efficacy data on novel agents used in the maintenance setting

Agenda - 1.25 hours
• Articles/Commentaries: 60 minutes
• Evaluation/Post-Test: 15 minutes


Physician Continuing Education Accreditation
This activity has been planned and implemented in accordance with the  Essential Areas and Policies of the Accreditation Council for Continuing Medical Edu cation (ACCME) through the joint sponsorship of Global Education Group (Global) and Medical Learning Institute, Inc. (MLI). Global is accredited by the ACCME to provide continuing medical education for physicians.


Physician Credit Designation
Global designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


Registered Nurse Designation
Medical Learning Institute, Inc.
Provider approved by the California Board of Registered Nursing, Provider 15106, for 1.25 contact hours.


Registered Pharmacy Designation
MLI is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. Completion of this activity provides for 1.25 contact hours (0.125 CEUs) of continuing education credit. The universal activity number for this activity is 0468-9999-11-015-H01-P.

Disclosure Statement
Before the activity, all faculty and anyone who is in a position to have control over the content of this activity and their spouse/life partner will disclose the existence of any financial interest and/or relationship(s) they might have with any commercial interest producing healthcare goods/services to be discussed during their presentation(s): honoraria, expenses, grants, consulting roles, speakers’ bureau membership, stock ownership, or other special relationships. Presenters will inform participants of any off-label discussions. All identified conflicts of interest are thoroughly vetted by Global for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:


Faculty Disclosures
Irene Ghobrial, MD has nothing to disclose.

*Janet Kunsman, MS, RN has nothing to disclose.

Houry Leblebjian, PharmD has nothing to disclose.

*Sagar Lonial, MD is a consultant for Bristol-Myers Squibb,  Celgene, Merck, Millennium Pharmaceuticals, Inc., Novartis, and Onyx.

*Content will include non-FDA-approved uses.

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:

Name of Planner
or Manager
Company Reported Financial
Relationship
Dana Delibovi COEXM Nothing to disclose
Jackie Dawson, MSN Global Nothing to disclose
Amanda Glazar, PhD Global Nothing to disclose
Nancy Nesser, JD, PharmD MLI Nothing to disclose
Ryan Sims, CRNA, MS MLI Nothing to disclose

Disclaimer
The information provided at this CME/CE activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient’s medical condition. Recommendations for the use of particular therapeutic agents are based on the best available scientific evidence and current clinical guidelines. No bias towards or promotion for any agent discussed in this program should be inferred.

Related Items
Recent Advances In The Treatment of Malignant Lymphoma: Updates From the Pan Pacific Lymphoma Conference
Irene M. Ghobrial, MD , Eric D. Jacobsen, MD, Xavier Leleu, MD, PhD, Aldo M. Roccaro, MD, PhD
Supplements published on January 16, 2012
Recent Advances In The Treatment of Malignant Lymphoma: Proceedings From a Post-ICML Roundtable
Irene M. Ghobrial, MD , Xavier Leleu, MD, PhD, VĂ©ronique Leblond, MD, PhD, Aldo M. Roccaro, MD, PhD
Supplements published on November 17, 2011
Considerations in Non-Hodgkin Lymphoma: Case Studies in Waldenstrom's Macroglobulinemia
Irene M. Ghobrial, MD , Houry Leblebjian, PharmD, Stacey Chuma, RN, BSN, Janet Kunsman, MS, RN
Supplements published on December 23, 2010
Last modified: March 21, 2014